An international research effort, led by a Cleveland Clinic doctor, has discovered the specific genetic alteration that is believed to cause a rare, but devastating vascular cancer. Brian Rubin, MD, PhD, of Cleveland Clinics Pathology and Laboratory Medicine Institute and Lerner Research Institute, helped devise an innovative approach to reveal the genetic clues to epithelioid hemangioendothelioma (EHE). The research was published in the Aug. 31 issue of Science Translational Medicine, and was done in collaboration with Cleveland Clinics Taussig Cancer Institute. The findings are also being used to develop a new diagnostic test for this blood vessel disease.
To continue reading this article or issue you must be a paid subscriber.
Sign in
